Passage Bio Financials - Benzinga

Passage Bio Inc

PASGNASDAQ

Trade with Public

Trade with Public

$4.53

0.0250.56%

Last update: Aug 27, 2:45 PM

Overview News Earnings Forecast Events Price TargetsFinancialsSentiment Ownership Compare Stock Report

Passage Bio Financials

Passage Bio (PASG) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

PRO
Passage Bio Q2 EPS $(2.44) Beats $(3.47) Estimate

Passage Bio (NASDAQ:PASG) reported quarterly losses of $(2.44) per share which beat the analyst consensus estimate of $(3.47) by 29.68 percent. This is a 17.57 percent increase over losses of $(2.96) per share from the

Benzinga Newsdesk

PRO
Passage Bio Q4 EPS $(4.09) Misses $(2.68) Estimate

Passage Bio (NASDAQ:PASG) reported quarterly losses of $(4.09) per share which missed the analyst consensus estimate of $(2.68) by 52.5 percent. This is a 2.25 percent decrease over losses of $(4.00) per share from the

Benzinga Newsdesk

PRO
Passage Bio Q3 EPS $(2.44) Beats $(2.80) Estimate

Passage Bio (NASDAQ:PASG) reported quarterly losses of $(2.44) per share which beat the analyst consensus estimate of $(2.80) by 12.86 percent. This is a 60.33 percent increase over losses of $(6.15) per share from the

Benzinga Newsdesk

PRO
Passage Bio Q2 EPS $(2.96) Misses $(0.21) Estimate

Passage Bio (NASDAQ:PASG) reported quarterly losses of $(2.96) per share which missed the analyst consensus estimate of $(0.21) by 1309.52 percent. This is a 41.85 percent increase over losses of $(5.09) per share from

Benzinga Newsdesk

PRO
Passage Bio Q1 EPS $(0.25) Misses $(0.23) Estimate

Benzinga Newsdesk

PRO
Passage Bio Q3 2024 GAAP EPS $(0.31) Misses $(0.28) Estimate, Cash, Cash Equivalents And Marketable Securities Were $84.8M Expected To Provide Cash Runway To The End Of Q2 2026

Passage Bio (NASDAQ:PASG) reported quarterly losses of $(0.31) per share which missed the analyst consensus estimate of $(0.28) by 10.71 percent. This is a 36.73 percent increase over losses of $(0.49) per share from the

Benzinga Newsdesk